Nov 21 |
Alzamend stock tumbles 18% in wake of clinical study update
|
Nov 20 |
Alzamend Neuro Receives FDA "Study May Proceed" Notification for a Phase IIA Clinical Trial of AL001, a Next‑Generation Lithium Therapeutic Drug Candidate, in Major Depressive Disorder Patients
|
Nov 16 |
Alzamend Neuro Regains Compliance with Nasdaq’s Minimum Bid Price Requirement
|
Nov 13 |
Alzamend Neuro Submits IND Application for a Phase IIA Clinical Trial in Post-Traumatic Stress Disorder Patients of Next‑Generation Lithium Therapeutic Drug Candidate AL001
|
Nov 13 |
EXCLUSIVE: Alzamend Neuro Seeks FDA Approval For Mid-Stage PTSD Study With Next‑Gen Lithium Therapeutic Drug Candidate
|